Q4 2020

Source filing unavailable

Q4 2020 · —

derived · Computed from the longer spans the company filed.

Revenue

$15.15M

derivedno prior Q4 2019 on file

Net Income

-$509.56M

derivedno prior Q4 2019 on file

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Incomederived-$540,834,000—

Same quarter

no prior Q4 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR